We are happy to invite to no less than two CCBIO Seminars Thursday February 21st, organized as part of the CCBIO/Harvard INTPART partnership. This gives us a unique opportunity to learn from the experiences of our Harvard colleagues. The seminars are open for all, including waffles and coffeebefore the first seminar, and informal pizza get togetherfollowing the afternoon seminar.
This time we are visited by Magali Saint-Geniezfrom Harvard Medical School and Schepens Eye Research Institute of Massachusetts, and Diane Bielenbergfrom the Vascular Biology Program, Boston Children’s Hospital, Department of Surgery, Harvard Medical School.
11.00-12.00 Magali Saint-Geniez: “Shining Light on the Metabolic Control of Retinal Diseases”. See abstract and bio in this link.
14.30-15.30 Diane Bielenberg: “Targeting Neuropilin Pathways to Inhibit Metastasis”. See abstract and bio in this link.
Where: Both will be in auditorium 4, BB-building, Jonas Lies vei 91, Bergen
No registration is required.
Sit in on other lectures:
Professors Saint-Geniez and Bielenberg are here in connection with the course in Cancer-Related Vascular Biology February 18-22, and for those who are interested, it is possible to sit in on other of their lectures the 18thand 19thwithout being enrolled to the course. You can see their lectures in this link. If you wish to sit in, please contact coordinator Elisabeth.firstname.lastname@example.org(limited seats).
Of general interest, we can particularly recommend the lecture at 14.00-15.00 Tuesday Feb. 19th, titled: “The “Science” of Branding; the value of a core message“. This aims to provide valuable and readily implementable tools to increase individual (students, researchers, PIs) marketability through personal branding, and highlight unique and special features that would particularly appeal to a potential recruiter or collaborator. Regarding the other lectures, professor Saint-Geniez’ lectures will be of particular interest to our ophthalmology environment, and Professor Bielenberg’s lectures will be of interest to all cancer researchers.